Head to Head Analysis: NeuroSense Therapeutics (NASDAQ:NRSN) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)

Mosaic ImmunoEngineering (OTCMKTS:CPMV) and NeuroSense Therapeutics (NASDAQ:NRSN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Insider & Institutional Ownership

1.0% of NeuroSense Therapeutics shares are held by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Mosaic ImmunoEngineering and NeuroSense Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mosaic ImmunoEngineering	0	0	0	0	0.00
NeuroSense Therapeutics	1	1	1	2	2.80

NeuroSense Therapeutics has a consensus price target of $14.00, indicating a potential upside of 1,407.97%. Given NeuroSense Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Mosaic ImmunoEngineering.

Valuation and Earnings

This table compares Mosaic ImmunoEngineering and NeuroSense Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mosaic ImmunoEngineering	N/A	N/A	-$920,000.00	($0.09)	-6.69
NeuroSense Therapeutics	N/A	N/A	-$10.21 million	($0.54)	-1.72

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mosaic ImmunoEngineering and NeuroSense Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mosaic ImmunoEngineering	N/A	N/A	-761.65%
NeuroSense Therapeutics	N/A	N/A	N/A

Volatility & Risk

Mosaic ImmunoEngineering has a beta of -0.82, meaning that its stock price is 182% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Summary

NeuroSense Therapeutics beats Mosaic ImmunoEngineering on 8 of the 11 factors compared between the two stocks.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.